<H1>Chapter DOI: 10.1007/s00105-015-3659-0<br/>Cited-By Count: 1</H1><table border="1" width="30%"><tr><td>Total References</td><td>46</td></tr><tr><td>Springer references</td><td>6</td></tr><tr><td>Non Springer references</td><td>40</td></tr><tr><td>BibStructured Count</td><td width="10%">46</td></tr><tr><td>BibUnstructured Count</td><td width="10%">0</td></tr><tr><td>DOI already available in SpringerLink</td><td>42</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>1</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>1</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>1</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>1</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Adler R, Garofalo G (2009) Ultrasound in the evaluation of the inflammatory myopathies. Curr Rheumatol Rep 11:302&#8211;308</td><td><a href=http://dx.doi.org/10.1007/s11926-009-0042-0>10.1007/s11926-009-0042-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibArticle</td><td>Aggarwal R, Oddis CV (2012) Therapeutic advances in myositis. Curr Opin Rheumatol 24:635&#8211;641</td><td><a href=http://dx.doi.org/10.1097/BOR.0b013e328358ac72>10.1097/BOR.0b013e328358ac72</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3</td><td>BibArticle</td><td>Amato AA for the Muscle Study Group (2011) A randomized, pilot trial of Etanercept in dermatomyositis. Ann Neurol 70:427&#8211;436</td><td><a href=http://dx.doi.org/10.1002/ana.22477>10.1002/ana.22477</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Ang GC, Werth VP (2005) Combination antimalarials in the treatment of 7cutaneous dermatomyositis. Arch Dermatol 141:835&#8211;839</td><td><a href=http://dx.doi.org/10.1001/archderm.141.7.855>10.1001/archderm.141.7.855</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5</td><td>BibArticle</td><td>Baechler EC, Bilgic H, Reed AM (2011) Type I interferon pathway in adult and juvenile dermatomyositis. Arthr Res Ther 13:249</td><td><a href=http://dx.doi.org/10.1186/ar3531>10.1186/ar3531</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Bendelwald MJ, Wetter DA, Xujian L, Davis MDP (2010) Incidence of dermatomyositis and clinically amyopathic dermatomyositis. Arch Dermatol 146:26&#8211;30</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR7</td><td>BibArticle</td><td>Bohan A, Peter JB (1975) Polymyositis and dermatomyositis. N Engl J Med 292:344&#8211;347 (und 403&#8211;407)</td><td><a href=http://dx.doi.org/10.1056/NEJM197502132920706>10.1056/NEJM197502132920706</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8</td><td>BibArticle</td><td>Callen JP (2000) Dermatomyositis. Lancet 355:53&#8211;57</td><td><a href=http://dx.doi.org/10.1016/S0140-6736(99)05157-0>10.1016/S0140-6736(99)05157-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Carstens PO, Schmidt J (2014) Diagnosis, pathogenesis and treatment of myositis: recent advances. Clin Exp Immunol 175:349&#8211;358</td><td><a href=http://dx.doi.org/10.1111/cei.12194>10.1111/cei.12194</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10</td><td>BibArticle</td><td>Casciola Rosen L, Mammen AL (2012) Myositis autoantibodies. Curr Opin Rheumatol 24:602&#8211;608</td><td><a href=http://dx.doi.org/10.1097/BOR.0b013e328358bd85>10.1097/BOR.0b013e328358bd85</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11</td><td>BibArticle</td><td>Curiel RV, Jones R, Brindle K (2009). Magnetic resonance imaging for idiopathic inflammatory myopathies: structural and clinical aspects. Ann NY Acad Sci 1154:101&#8211;114</td><td><a href=http://dx.doi.org/10.1111/j.1749-6632.2009.04386.x>10.1111/j.1749-6632.2009.04386.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12</td><td>BibArticle</td><td>Dalakas MC, Illa I, Dambrosia JM et al (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993&#8211;2000</td><td><a href=http://dx.doi.org/10.1056/NEJM199312303292704>10.1056/NEJM199312303292704</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13</td><td>BibArticle</td><td>Danieli MG, Pettinari L, Moretti R et al (2011) Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev 10:144&#8211;149</td><td><a href=http://dx.doi.org/10.1016/j.autrev.2010.09.004>10.1016/j.autrev.2010.09.004</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14</td><td>BibArticle</td><td>Enk A, the European Dermatology Forum Guideline Subcommittee (2009) Guidelines on the use of high-dose intravenous immunoglobulin in dermatology. Eur J Dermatol 19:90&#8211;98</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR15</td><td>BibArticle</td><td>Euwer RL, Sontheimer RB (1991) Amyopathic dermatomyositis (dermatomyositis sine myositis). Presentation of six new cases and review oft he literature. J Am Acad Dermatol 24:959&#8211;966</td><td><a href=http://dx.doi.org/10.1016/0190-9622(91)70153-S>10.1016/0190-9622(91)70153-S</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16</td><td>BibArticle</td><td>Fernandez C, Bardin N, Maues De, Paula A et al (2013) Correlation of clinicoserologic and pathologic classifications of inflammatory myopathies. Medicine 92:15&#8211;24</td><td><a href=http://dx.doi.org/10.1097/MD.0b013e31827ebba1>10.1097/MD.0b013e31827ebba1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17</td><td>BibArticle</td><td>Garcia J (2000) MRI in inflammatory myopathies. Skeletal Radiol 29:425&#8211;438</td><td><a href=http://dx.doi.org/10.1007/s002560000238>10.1007/s002560000238</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18</td><td>BibArticle</td><td>G&#246;ttfried I, Seeber A, Anegg B et al (2000) High dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels. Eur J Dermatol 10:29&#8211;35</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR19</td><td>BibArticle</td><td>Greenberg SA et al (2010) Dermatomyositis and type 1 interferons. Curr Rheumatol Rep 12:198&#8211;203</td><td><a href=http://dx.doi.org/10.1007/s11926-010-0101-6>10.1007/s11926-010-0101-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20</td><td>BibArticle</td><td>Hausmann G, Herrero C, Cid MC et al (1991) Immunopathologic study of skin lesions in dermatomyositis. J Am Acad Dermatol 25:225&#8211;230</td><td><a href=http://dx.doi.org/10.1016/0190-9622(91)70186-6>10.1016/0190-9622(91)70186-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21</td><td>BibArticle</td><td>Higgs BW, Zhu W, Morehouse C et al (2013) A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-a monoclonal antibody, shows target neutralisation of a type I signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 73:256&#8211;262</td><td><a href=http://dx.doi.org/10.1136/annrheumdis-2012-202794>10.1136/annrheumdis-2012-202794</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22</td><td>BibArticle</td><td>Hill CL, Zhanf Y, Sigurgeirrson B et al (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357:96&#8211;100</td><td><a href=http://dx.doi.org/10.1016/S0140-6736(00)03540-6>10.1016/S0140-6736(00)03540-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23</td><td>BibArticle</td><td>Hornung T, Janzen V, Wenzel J (2014) Remission of recalcitrant dermatomyositis treated with Ruxolitinib. N Engl J Med 371:2537&#8211;2538</td><td><a href=http://dx.doi.org/10.1056/NEJMc1412997>10.1056/NEJMc1412997</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24</td><td>BibArticle</td><td>Jorizzo LJ, Jorizzo JI (2008) The treatment and prognosis of dermatomyositis: an updated review. J Am Acad Dermatol 59:99&#8211;112</td><td><a href=http://dx.doi.org/10.1016/j.jaad.2008.02.043>10.1016/j.jaad.2008.02.043</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25</td><td>BibArticle</td><td>Kazuki T, Bookbinder S, Furie R (2002) A &#252;ilot study of eculizumab in patients with dermatomyositis. Arthritis Res 46:S489</td><td><a href=http://dx.doi.org/10.1002/art.10125>10.1002/art.10125</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26</td><td>BibArticle</td><td>Kim JE, Jeong MG, Lee HE et al (2011) Successful treatment of cutaneous lesions of dermatomyositis with topical pimecrolimus. Ann Dermatol 23:348&#8211;351</td><td><a href=http://dx.doi.org/10.5021/ad.2011.23.3.348>10.5021/ad.2011.23.3.348</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27</td><td>BibArticle</td><td>Kissel JT, Mendell JR, Rammohan KW (1986) Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 314:329&#8211;334</td><td><a href=http://dx.doi.org/10.1056/NEJM198602063140601>10.1056/NEJM198602063140601</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28</td><td>BibArticle</td><td>Kovacs SO, Kovacs C (1998) Dermatomyositis. J Am Acad Dermatol 39:899&#8211;920</td><td><a href=http://dx.doi.org/10.1016/S0190-9622(98)70263-4>10.1016/S0190-9622(98)70263-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR29</td><td>BibArticle</td><td>Levine T (2012) Treating refractory dermatomyositis and polymyositis with adrenocorticotropic hormine gel: a retrospective case series. Drug Des Devel Ther 6:133&#8211;139</td><td><a href=http://dx.doi.org/10.2147/DDDT.S33110>10.2147/DDDT.S33110</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30</td><td>BibArticle</td><td>Love LA, Leff RL, Fraser DD et al (1991) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogenous patient groups. Medicine 70:360&#8211;374</td><td><a href=http://dx.doi.org/10.1097/00005792-199111000-00002>10.1097/00005792-199111000-00002</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31</td><td>BibArticle</td><td>Magro CM, Dyrsen M., Kerns MJ (2008) Cutaneous lesions of dermatomyositis with supervening fibrosis. J Cutan Pathol 35:31&#8211;39</td><td><a href=http://dx.doi.org/10.1111/j.1600-0560.2007.00770.x>10.1111/j.1600-0560.2007.00770.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, JournalTitle, Author_FamilyName_2, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR32</td><td>BibArticle</td><td>Malmstr&#246;m V, Venalis P, Albrecht I (2012) T cells in myositis. Arthritis Res Ther 14:230&#8211;236</td><td><a href=http://dx.doi.org/10.1186/ar4116>10.1186/ar4116</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR33</td><td>BibArticle</td><td>Mascaro JM Jr, Hausmann G, Herrero C et al (1995) Membrane attack complex deposits in cutaneous lesions of dermatomyositis. Arch Dermatol 131:1386&#8211;1392</td><td><a href=http://dx.doi.org/10.1001/archderm.1995.01690240040007>10.1001/archderm.1995.01690240040007</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR34</td><td>BibArticle</td><td>Mathur T, Manadan AM, Thiagarajan S et al (2014) The utility of serum aldolase in normal creatine kinase dermatomyositis. J Clin Rheumatol 20:47&#8211;48</td><td><a href=http://dx.doi.org/10.1097/RHU.0000000000000062>10.1097/RHU.0000000000000062</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR35</td><td>BibArticle</td><td>McCann LJ, Juggins AD, Maillard SM et al (2006) The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland) &#8211; clinical characteristics of children recruited within the first 5 yr. Rheumatology 45:1255&#8211;1260</td><td><a href=http://dx.doi.org/10.1093/rheumatology/kel099>10.1093/rheumatology/kel099</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR36</td><td>BibArticle</td><td>Mendez EP, Lipton R, Ramsey-Goldman R et al (2003) US Incidence of juvenile dermatomyositis. 1995&#8211;1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 49:300&#8211;305</td><td><a href=http://dx.doi.org/10.1002/art.11122>10.1002/art.11122</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37</td><td>BibArticle</td><td>Meyer A, Meyer N, Schaeffer M et al (2015) Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology 54:50&#8211;63</td><td><a href=http://dx.doi.org/10.1093/rheumatology/keu289>10.1093/rheumatology/keu289</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR38</td><td>BibArticle</td><td>Oddis CV, Reed AM, Aggarwal R et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase Trial. Arthritis Rheum 65:314&#8211;324</td><td><a href=http://dx.doi.org/10.1002/art.37754>10.1002/art.37754</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR39</td><td>BibArticle</td><td>Peter A, Balogh A, Szilagyi S et al (2015) Echocardiographic abnormalities in new-onset polymyositis/dermatomyositis. J Rheumatol 42:272&#8211;281</td><td><a href=http://dx.doi.org/10.3899/jrheum.140626>10.3899/jrheum.140626</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR40</td><td>BibArticle</td><td>Sato S, Kuwana M, Fuijita T et al (2013) Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol 23:496&#8211;502</td><td><a href=http://dx.doi.org/10.3109/s10165-012-0663-4>10.3109/s10165-012-0663-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR41</td><td>BibArticle</td><td>Tanizawa K, Handa T, Nakashima R et al (2011) HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Resp Med 105:1380&#8211;1387</td><td><a href=http://dx.doi.org/10.1016/j.rmed.2011.05.006>10.1016/j.rmed.2011.05.006</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR42</td><td>BibArticle</td><td>Troyanov Y, Targoff IN, Payette M-P et al (2014) Redefining Dermatomyositis. A description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features. Medicine 93:318&#8211;332</td><td><a href=http://dx.doi.org/10.1097/MD.0000000000000222>10.1097/MD.0000000000000222</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR43</td><td>BibArticle</td><td>Ueda M, Makinodan R, Matsumura M, Ichihashi M (2003) Successful treatment of amyopathic dermatomyositis with topical tacrolimus. Br J Dermtol 148:595&#8211;596</td><td><a href=http://dx.doi.org/10.1046/j.1365-2133.2003.05209_4.x>10.1046/j.1365-2133.2003.05209_4.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR44</td><td>BibArticle</td><td>Wiesinger GF, Quittan M, Aringer M et al (1998) Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme. Br J Rheumatol 37:196&#8211;200</td><td><a href=http://dx.doi.org/10.1093/rheumatology/37.2.196>10.1093/rheumatology/37.2.196</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR45</td><td>BibArticle</td><td>Winklehner A, Berger N, Maurer B et al (2012) Screening for interstitial lung disease in systemic sclerosis: the diagnostic accuracy of HRCT image series with high increment and reduced number of slices. Ann Rheum Dis 71:549&#8211;552</td><td><a href=http://dx.doi.org/10.1136/annrheumdis-2011-200564>10.1136/annrheumdis-2011-200564</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR46</td><td>BibArticle</td><td>Zahr ZE, Baer AN (2011) Malignancy in myositis. Curr Rheumatol Rep 13:208&#8211;215</td><td><a href=http://dx.doi.org/10.1007/s11926-011-0169-7>10.1007/s11926-011-0169-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>